Cargando…

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis

BACKGROUND: Rituximab (RTX) and ocrelizumab (OCR) are two anti-CD20 biologics used in MS; however, comparisons on safety and efficacy are rare. OBJECTIVE: To compare treatment outcomes over the first year with RTX and OCR. METHODS: Retrospective cohort study comprising MS patients initiating RTX at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evertsson, Björn, Hoyt, Tammy, Christensen, Angel, Nimer, Faiez AL, Foley, John, Piehl, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556182/ https://www.ncbi.nlm.nih.gov/pubmed/33110619 http://dx.doi.org/10.1177/2055217320964505

Ejemplares similares

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
por: Duell, Frida, et al.
Publicado: (2020)

Copy number variations across the blood–brain barrier in multiple sclerosis
por: Bedri, Sahl Khalid, et al.
Publicado: (2022)

Ocrelizumab/rituximab: Various toxicities: 6 case reports
Publicado: (2021)

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions
por: Alvarez, Enrique, et al.
Publicado: (2022)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Ocrelizumab/rituximab: COVID-19 infection: 2 case reports
Publicado: (2021)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures
por: Günther, Mattias, et al.
Publicado: (2018)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients
por: Asplund Högelin, Klara, et al.
Publicado: (2022)

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
por: Reddy, Venkat, et al.
Publicado: (2013)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis
por: Aeinehband, Shahin, et al.
Publicado: (2015)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
por: Khademi, Mohsen, et al.
Publicado: (2013)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1sckud44g2b2iq39p5vts974c